Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Palvella Therapeutics (PVLA) News Today

Palvella Therapeutics logo
$53.42 +2.11 (+4.11%)
As of 08/22/2025 04:00 PM Eastern
Compare

PVLA Latest News

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Brokerages
August 24 at 5:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-inc-nasdaqpvla-given-consensus-recommendation-of-buy-by-brokerages-2025-08-22/
Institutional investors in Palvella Therapeutics, Inc. (NASDAQ:PVLA) have had a wonderful week after share price increased 13%
August 23 at 3:49 PM  |  finance.yahoo.comhttps://finance.yahoo.com/news/institutional-investors-palvella-therapeutics-inc-143901424.html
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 5.7% After Analyst Upgrade
August 22 at 2:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30290375
Canaccord Genuity Group Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $66.00
August 21 at 10:33 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/canaccord-genuity-group-raises-palvella-therapeutics-nasdaqpvla-price-target-to-6600-2025-08-19/
Palvella Therapeutics (NASDAQ:PVLA) Reaches New 12-Month High - Here's What Happened
August 21 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-reaches-new-12-month-high-heres-what-happened-2025-08-19/
Canaccord Genuity Group Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock
August 21 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30289181
Palvella Therapeutics price target raised to $66 from $52 at Canaccord
August 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/palvella-therapeutics-price-target-raised-to-66-from-52-at-canaccord/ar-AA1KO68V
Palvella Therapeutics (NASDAQ:PVLA) Announces Quarterly Earnings Results
August 18, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-announces-quarterly-earnings-results-2025-08-16/
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $60.00
August 18, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30282993
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
August 17, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PVLA/pressreleases/34200661/truist-financial-sticks-to-its-buy-rating-for-palvella-therapeutics-pvla/
HC Wainwright Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price
August 17, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-palvella-therapeutics-nasdaqpvla-stock-price-2025-08-15/
Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price
August 17, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/chardan-capital-issues-positive-forecast-for-palvella-therapeutics-nasdaqpvla-stock-price-2025-08-15/
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 3.6% - Time to Buy?
August 16, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-shares-up-36-time-to-buy-2025-08-14/
Palvella Therapeutics (NASDAQ:PVLA) Reaches New 1-Year High - Still a Buy?
August 15, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-reaches-new-1-year-high-still-a-buy-2025-08-13/
Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright
August 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/palvella-therapeutics-price-target-raised-to-75-from-38-at-h-c-wainwright/ar-AA1KBhQS
Palvella Therapeutics price target raised to $60 from $50 at Chardan
August 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/palvella-therapeutics-price-target-raised-to-60-from-50-at-chardan/ar-AA1KyOp9
Palvella Therapeutics price target raised to $60 from $45 at Stifel
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/palvella-therapeutics-price-target-raised-to-60-from-45-at-stifel/ar-AA1KxQyi
Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)
August 14, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/palvella-therapeutics-reports-q2-eps-86c-consensus-77c/ar-AA1KwV8N
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/14/3133348/0/en/palvella-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update.html
Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129133/0/en/palvella-therapeutics-to-host-second-quarter-2025-financial-results-and-corporate-update-conference-call-on-august-14-2025.html
Analysts Issue Forecasts for PVLA Q2 Earnings
August 7, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analysts-issue-forecasts-for-pvla-q2-earnings-2025-08-06/
Palvella Therapeutics (PVLA) to Release Earnings on Wednesday
August 7, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-pvla-to-release-earnings-on-wednesday-2025-08-06/
Palvella Therapeutics initiated with an Outperform at Raymond James
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/palvella-therapeutics-initiated-with-an-outperform-at-raymond-james/ar-AA1K1cE5
Raymond James Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/raymond-james-initiates-coverage-of-palvella-therapeutics-pvla-with-outperform-recommendation/ar-AA1K2aYv
LifeSci Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation
August 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/lifesci-capital-initiates-coverage-of-palvella-therapeutics-pvla-with-outperform-recommendation/ar-AA1JV3IP
Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated by Analysts at Lifesci Capital
August 5, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-coverage-initiated-by-analysts-at-lifesci-capital-2025-08-04/
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/05/3127237/0/en/palvella-therapeutics-to-participate-in-the-canaccord-genuity-45th-annual-growth-conference.html
Royce & Associates LP Invests $2 Million in Palvella Therapeutics, Inc. (NASDAQ:PVLA)
July 29, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royce-associates-lp-invests-2-million-in-palvella-therapeutics-inc-nasdaqpvla-2025-07-29/
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Brokerages
July 28, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-inc-nasdaqpvla-receives-consensus-rating-of-buy-from-brokerages-2025-07-28/
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist Financial
July 21, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-now-covered-by-truist-financial-2025-07-21/
PVLA - Palvella Therapeutics Inc Sustainability - Morningstar
July 9, 2025  |  morningstar.comM
Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin
July 9, 2025  |  msn.comhttps://www.msn.com/en-us/health/medical/palvella-therapeutics-completes-enrollment-for-pivotal-phase-3-trial-of-qtorin-rapamycin/ar-AA1IgeYn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts
July 3, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-inc-nasdaqpvla-given-consensus-recommendation-of-buy-by-analysts-2025-07-03/
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
June 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/30/3107382/0/en/palvella-therapeutics-added-to-russell-3000-and-russell-2000-indexes.html
Strid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)
June 29, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-strid-group-llc-takes-818000-position-in-palvella-therapeutics-inc-nasdaqpvla-2025-06-29/
PVLA - Palvella Therapeutics Inc Key Metrics - Morningstar
June 27, 2025  |  morningstar.comM
PVLA - Palvella Therapeutics Inc Executives - Morningstar
June 26, 2025  |  morningstar.comM
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - Morningstar
June 24, 2025  |  morningstar.comM
Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - Nasdaq
June 24, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/palvella-therapeutics-completes-enrollment-phase-3-trial-qtorintm-rapamycin-microcystic
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin
June 24, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/palvella-therapeutics-announces-completion-of-phase-3-selva-trial-for-qtorin-rapamycin/ar-AA1HiGtA
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
June 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/23/3103284/0/en/palvella-therapeutics-completes-enrollment-in-phase-3-selva-trial-of-qtorin-rapamycin-for-microcystic-lymphatic-malformations-exceeding-enrollment-target-by-over-25.html
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101359/0/en/palvella-therapeutics-granted-sixth-u-s-patent-covering-0-1-20-anhydrous-compositions-of-rapamycin-and-other-mtor-inhibitors.html
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin
June 13, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/palvella-therapeutics-secures-fda-grant-funding-for-phase-3-trial-of-qtorin-rapamycin/ar-AA1GvTKA
Cantor Fitzgerald Comments on PVLA FY2026 Earnings
June 11, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cantor-fitzgerald-comments-on-pvla-fy2026-earnings-2025-06-11/
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
June 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/09/3095755/0/en/palvella-therapeutics-receives-initial-proceeds-from-fda-orphan-products-grant-to-support-phase-3-selva-trial-of-qtorin-rapamycin-for-microcystic-lymphatic-malformations.html
Citadel Advisors LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)
June 9, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-citadel-advisors-llc-makes-new-investment-in-palvella-therapeutics-nasdaqpvla-2025-06-09/
Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts
June 8, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/palvella-therapeutics-nasdaqpvla-given-consensus-recommendation-of-buy-by-analysts-2025-06-08/
Toronto Dominion Bank Buys Shares of 13,211 Palvella Therapeutics (NASDAQ:PVLA)
June 2, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-toronto-dominion-bank-buys-shares-of-13211-palvella-therapeutics-nasdaqpvla-2025-06-02/
Palvella Therapeutics Advances in Rare Skin Disease Therapies
May 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/palvella-therapeutics-advances-in-rare-skin-disease-therapies?utm_source=marketbeat.com&utm_medium=referral
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088554/0/en/palvella-therapeutics-strengthens-executive-leadership-team-with-appointment-of-rare-disease-commercial-veteran-ashley-kline-as-chief-commercial-officer.html
Get Palvella Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.

PVLA Media Mentions By Week

PVLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PVLA
News Sentiment
▼
0.78

0.69
▲
Average
Medical
News Sentiment

PVLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PVLA Articles
This Week
▼
11

4
▲
PVLA Articles
Average Week

Get Palvella Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:PVLA) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...
Brownstone Research | Sponsoredtc pixel
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsoredtc pixel
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsoredtc pixel
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...
Investors Alley | Sponsoredtc pixel
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsoredtc pixel
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsoredtc pixel